DRTSW | Alpha Tau Medical Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2376 - 0.2376
52 Week Range	0.2376 - 0.2376
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	120
Average Volume	20,108
Shares Outstanding	70,380,600
Market Cap	16,722,431
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	121
Country	Israel
Website	DRTSW

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.

DRTSW's peers: EYPT, DRTS, EFTRW, EQRXW, REVBW, GRNAW, PRENW, NWTNW, EUDAW

*Chart delayed

Analyzing fundamentals for DRTSW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see DRTSW Fundamentals page.

Watching at DRTSW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on DRTSW Technicals page.